Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer

By sjmartinez • July 14, 2024

Preston MA, Ebrahimi R, Hong A, Bobbili P, Desai R, Duh MS, Gandhi R, Hanson S, Dufour R, Morgans AK. Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer. Urol Oncol. 2024 Jul 12:S1078-1439(24)00499-X. doi: 10.1016/j.urolonc.2024.05.026. Epub ahead of print. PMID: 39003108.

Tags: Androgen deprivation therapy, Cardiology/Epi, cardiovascular risk, Continuous ADT, Endocrine or metabolic risk, Intermittent ADT, Nonmetastatic prostate cancer, Publications, Veterans Administration

Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension

McLaughlin VV, Howard L, Elwing J, Fernandes CC, Gaine S, Galiè N, Oudiz RJ, Stefani M, Stickel S, Strachan P, Tamura Y, Kim NH. Evaluating[...]

Decontrasted Image Registration Improves Quantification of Extracellular Volume and Fractional Myocardial Blood Volume

Lu M, Mahmoudi M, Nguyen KL, Xie Y. Decontrasted Image Registration Improves Quantification of Extracellular Volume and Fractional Myocardial Blood Volume. NMR Biomed. 2025 Dec;38(12):e70179.[...]

Author Correction: Kilohertz volumetric imaging of in vivo dynamics using squeezed light field microscopy

Wang Z, Zhao R, Wagenaar DA, Espino D, Sheintuch L, Benshlomo O, Kang W, Zhu E, Lee CK, Schmidt WC, Pammar A, Wang J, Wong[...]